Our teams

Patrick Krol, Portfolio Manager

Patrick has been a private investor in public biotech companies for over 30 years. Since 2005 he is active at Aescap as a professional investor in biotech / life sciences companies. He acted as a board director of 10 biotech and medical diagnostics companies.

From 1995 to 2004 Patrick was managing director of Firm United Healthcare B.V., a consultancy company that provided market research, strategy and communication advice to the biotech / life sciences industry. Over the 9 years Patrick led the company it became a market leader on the European continent and guided over 35 public pharma and biotech companies to successfully introduce or grow their medicines. He currently applies his expertise to successfully select and guide Aescap’s investments.

Patrick studied physical therapy, followed by business administration. Later in his career he completed an MBA from LMS.

Michaël Mellink, Investment Partner

Michaël joined Aescap as Investment partner in 2021. He worked in senior commercial and management positions roles at big pharma Eli Lilly before he became the general manager for the Benelux operations next to responsibilities for European business development at Cephalon, a U.S. biopharmaceutical company.

He is also active as a Senior Partner of the global life sciences practice at one of the global leading executive search firms in the biotech sector, Odgers Berndtson. He is advising clients on board and senior level appointments for pharma, biotech, medtech and service companies and works across international markets and a broad range of companies in the industry. Michaël holds a Bachelor’s degree in physiotherapy and has studied orthopaedic medicine.

Paolo del Bufalo, Analyst

Paolo obtained a Bachelor’s degree in Chemistry at La Sapienza University of Rome after which he completed two Master tracks at Leiden University, one in Chemical Biology Research and one in Science Based Business. Throughout his academic research career he focused on supramolecular chemistry and photochemistry for applications in medicinal chemistry. During his business studies, he acquired knowledge to combine his scientific background with the business environment, particularly with value investing. Paolo joined Aescap Life Sciences as an analyst in 2018.

Tristan Maguet, Analyst

Tristan holds a Pharm.D from the University of Grenoble Alpes and a MSc in Management from ESSEC Business School in Paris. During his pharmaceutical studies, Tristan specialized in the biotechnology industry and led a project where he went through all stages of development and registration for human growth hormone. Tristan developed his knowledge in the healthcare industry during his internships at Aescap Life Sciences as an analyst and at venture capital fund Andera Partners in their BioDiscovery franchise as a biotech and medtech analyst. Tristan joined Aescap Life Sciences as an analyst in 2019.

Etienne Daher, Analyst

Etienne holds a PharmD from the University of Grenoble Alpes and an advanced master in Corporate Strategy and Management from ESSEC Business School in Paris. Etienne started his career as an analyst intern for Merck Ventures in Amsterdam, he then joined the French Sovereign Wealth Fund (Bpifrance) in Paris as a consultant where he provided operational and strategic support to biotech, medtech and digital health companies in the investment portfolio of Bpifrance. He then moved on to become Chief of Staff at Sensorion, a company developing gene therapies. Etienne joined Aescap in June 2021.

Patricia Allam, Head of Investor Relations

Patricia joined Aescap Life Sciences in early 2021 after working in client facing roles for over 8 years with Danske Bank and Tessin Nordic. During those years she worked together with a diverse set of investors globally, from institutional to family offices and HNW. Patricia has a broad outreach especially in the Nordics from her previous working experiences in Copenhagen, Helsinki, and Stockholm. She has an MSc in Finance and Accounting and earned an MBA from IMD Business School in Lausanne in 2017.

Bo Jesper Hansen, Portfolio Advisor

Bo Jesper, M.D., Ph.D. was the Executive Chairman of the Board of SOBI AB (Swedish Orphan Biovitrum AB) until 2016. SOBI is a biotech company listed on the Swedish stock exchange and at the time had a market capitalization of around 3,5 billion euros. He is Chairman of Karolinska Development AB and is also non-executive Director of the biotech company Orphazyme ApS. Bo Jesper served as CEO and President to the Board of Swedish Orphan International (1998-2010) until the merger with Biovitrum, forming Swedish Orphan Biovitrum. He then became the company’s executive chairman. He also was non-executive Director of Gambro until its acquisition by Baxter, as well as of Zymenex, until its acquisition by Chiesi. Bo Jesper was the Executive Chairman of Ablynx until its acquisition by Sanofi, as well as of Topotarget and in this role led the merger with BioAlliance forming OnXeo. He founded Scandinavian Medical Research during which he served as Medical Advisor for the multinationals Synthélabo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical. He has also been a board member with the companies TopoTarget A/S, CMC AB, MipSalus Aps, Kontrast AB, Hyperion Therapeutics, Inc. Newron Pharmaceuticals S.p.A, Novagali Pharma S.A. and VivolutionA/S.

Bo Jesper has an extensive knowledge within clinical study design, regulatory, pharmacovigilance, and business development. He has an M.D. in Urology and a PhD from the University of Copenhagen. Patrick and Bo Jesper first met in 2012 as members of the supervisory board of biotech company Orphazyme S.p.A.

Fred Oudshoorn, Portfolio Advisor

Fred is the founder and managing director of Jonghoud BV, an investment firm in amongst others, equity of private and listed healthcare companies. As a pharmacist he built a chain of 40 pharmacies “De Vier Vijzels” which was later acquired by Alliance Unichem. He is also a founder of MediZorg, the former chairman of Sinensis Laboratoria and supervisory board member of Kadans and Kadans Science Partners. Patrick and Fred first met in their function as supervisory board members back in 2012 and soon discovered their mutual activities in investing in public innovative medical companies.

Gert Hoogland, Portfolio Advisor

Gert, M.D., MBA (INSEAD) is a pharmaceutical executive with deep operational experience. He began his career in 1982 as Medical Advisor to Organon NV in Oss, The Netherlands, followed by CEO positions for Schering AG in New Zealand and South Africa. He then founded Pharmaplan Pty Ltd in Johannesburg, which became the leading specialty pharma distributor in Africa representing biotech companies like Biogen, Bracco, Recordati, Ipsen, Genzyme and Shire. After the sale of this company to the Canadian Specialty Pharma company Paladin Inc. Gert relocated to Zurich to start HealthCrest AG, a healthcare investment and consulting company. He has initiated investments in many private and public healthcare companies, geographically encompassing Europe, India, China, the US and Africa and continues to serve on the Board of many of these portfolio companies. Patrick and Gert first met in 2013 as investors in i-Optics BV.

Michiel de Haan, Fund Advisor

Michiel has been active in life sciences since 1987 when he spun-out Atlas Venture from the ING bank. Under his leadership Atlas developed into a European-American venture capital firm with offices in Amsterdam, Munich, Boston and London and invested in over 300 venture backed companies in Information Technology and Life Sciences. He has been active on numerous boards of Life Science companies such as Crucell and Morphosys.

Michiel is past chairman of the European Venture Capital Association (EVCA) and co-founder of the European Venture Philanthropy Association (EVPA). In 1974 Michiel received an MBA from Erasmus University in Rotterdam. From 1974 until 1980 he worked at NMB (now ING). Michiel started NMB-Participatie, which he later bought to create Atlas Venture. Currently he is General Partner of Aescap Venture that he co-founded together with Dinko Valerio in 2005 and is a fund advisor to Aescap Life Sciences.

Our team